Does extra alemtuzumab remove the graft-versus-leukemia effect after allogeneic stem cell transplantation in chronic lymphocytic leukemia?

Biol Blood Marrow Transplant. 2009 Apr;15(4):517-8. doi: 10.1016/j.bbmt.2008.12.511.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Cohort Studies
  • Cyclosporine / administration & dosage
  • Cytomegalovirus
  • Cytomegalovirus Infections
  • Disease-Free Survival
  • Donor Selection
  • Female
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / prevention & control*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Living Donors
  • Lymphocyte Depletion
  • Male
  • Middle Aged
  • Myeloablative Agonists / administration & dosage
  • Retrospective Studies
  • Survival Rate
  • T-Lymphocytes
  • Transplantation Conditioning
  • Transplantation, Homologous
  • Virus Activation / drug effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Myeloablative Agonists
  • Alemtuzumab
  • Cyclosporine